Eli Lilly and CNIO are collaborating on the discovery of new targets for development of potential cancer therapeutics. We are seeking Research Scientists who will integrate into a group at CNIO to evaluate and validate new cancer targets in the emerging area of Tumor Metabolism, Immunotherapy and oncogenic signaling.
Roles and responsabilities of the position:
• Molecular and Cellular biology: experiments involving cell culture of human and mouse cells for target validation, biochemistry and molecular biology particularly cloning, retroviral expression systems and CRISPR technology.
• Advanced experience in animal models in particular tumor animal models both spontaneous tumor formation as well as xenograft/allograft models. Ample experience in regular molecular biology techniques as well as cloning.
• Generation, screening and analysis of cDNA and shRNA libraries.
• CRISPR technology.
Se Requiere
- PhD degree in a biomedical discipline.
- Postdoctoral research experience either in pharmaceutical industry or a top academic laboratory.
- Experience in animal models.
- Experience in cell culture and target modulation, biochemistry and molecular biology, CRISPR and RNA seq.
- Experience in FACS analysis, immune cells isolation and characterization.
- Handling and analysis of histopathological samples for human and mouse tissues.
- Multiplexed immunohistochemistry, imaging, and quantification.
- Fluent in English.
Se Ofrece
- An opportunity to be part of one of the few European Cancer Research Centres of excellence that effectively combines basic and applied research.
- An energetic working environment with a multidisciplinary approach to drug discovery, equipped with state-of-the-art technology.
- A competitive salary commensurate with the candidates experience and qualifications as well as an attractive benefits package.
- Contract linked to a project.
via CNIO. Empleo Más Información Aquí...
